Benjamin Hickey
President bij RAYZEBIO, INC.
Vermogen: 47 234 $ op 31-03-2024
Profiel
Mr. Benjamin J.
Hickey is a President at Rayzebio, Inc. and an Independent Director at Mural Oncology Plc.
He is on the Board of Directors at Mural Oncology Plc and Bristol-Myers Squibb Holdings 2002 Ltd.
Mr. Hickey was previously employed as an Independent Director by Surface Oncology, Inc., a Chief Commercial Officer by Mirati Therapeutics, Inc., and a Chief Commercial Officer & Senior Vice President by Halozyme Therapeutics, Inc. He also served on the board at Bristol-Myers Squibb Pharmaceuticals Ltd.
He received his undergraduate degree from St. John's University and an MBA from St. John's University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
10-03-2024 | 871 ( 0.00% ) | 47 234 $ | 31-03-2024 | |
-.--% | 01-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Benjamin Hickey
Bedrijven | Functie | Begin |
---|---|---|
RAYZEBIO, INC. | President | 26-02-2024 |
Bristol-Myers Squibb Holdings 2002 Ltd.
Bristol-Myers Squibb Holdings 2002 Ltd. Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings 2002 Ltd. is a holding British company that operates subsidiaries distributing and selling pharmaceutical products. The private company is based in Uxbridge, UK. | Director/Board Member | 01-08-2016 |
Eerdere bekende functies van Benjamin Hickey
Bedrijven | Functie | Einde |
---|---|---|
MIRATI THERAPEUTICS | Corporate Officer/Principal | 23-01-2024 |
SURFACE ONCOLOGY, INC. | Director/Board Member | 08-09-2023 |
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2020 |
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Director/Board Member | 03-09-2018 |
Opleiding van Benjamin Hickey
St. John's University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Health Technology |
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Bristol-Myers Squibb Holdings 2002 Ltd.
Bristol-Myers Squibb Holdings 2002 Ltd. Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings 2002 Ltd. is a holding British company that operates subsidiaries distributing and selling pharmaceutical products. The private company is based in Uxbridge, UK. | Distribution Services |